UCLA Cashes in on Drug Sale

UCLA will receive a hefty payday for its role in developing a prostate cancer drug. According to the Los Angeles Times, New York´s Royal Pharma paid $1.14 billion for royalty rights to the drug known as Xtandi, with UCLA expected to pocket $520 million of the proceeds.